サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1635967

免疫チェックポイント阻害薬市場レポート：タイプ別、流通チャネル別、用途別、地域別、2025-2033年

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 124 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
免疫チェックポイント阻害薬市場レポート：タイプ別、流通チャネル別、用途別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 124 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫チェックポイント阻害薬の市場の世界市場規模は2024年に495億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は14.6％で、2033年には1,686億米ドルに達すると予測しています。さまざまながんの有病率の上昇、呼吸器疾患の増加、個別化された医薬品への嗜好の高まりなどが、市場を牽引する主な要因となっています。

免疫チェックポイント阻害薬は、T細胞やがん細胞などの免疫系細胞によって作られる特定のタンパク質を阻害することにより、がんの治療に利用される薬剤です。単独で、あるいは化学療法や放射線療法など他のがん治療と組み合わせて使用され、治療効果を高める。免疫チェックポイント阻害薬は、病気の症状を軽減し、生存期間を延長することで、がん患者の生活の質を高めるのに役立ちます。免疫チェックポイント阻害薬は、免疫系の特定の経路を標的とするため、より標的を絞ったがん治療が可能となります。これらの阻害薬は、従来の化学療法と比較して、副作用が少なく、患者の忍容性を高める低毒性プロファイルを持っています。現在、がん細胞内の特定の遺伝子変異の同定を可能にする次世代シークエンシング技術の利用が増加しており、これが世界中で免疫チェックポイント阻害薬の需要を喚起しています。

免疫チェックポイント阻害薬の市場傾向：

メラノーマ、肝臓がん、腎臓がん、胃がんなど、さまざまながんの罹患率が急増していることは、世界中で免疫チェックポイント阻害薬の需要を押し上げている主な要因のひとつです。さらに、このような重篤ながんを発症しやすい高齢化人口の増加や肥満の有病率の上昇が、市場の成長を後押ししています。さらに、アルコール飲料やタバコの消費量の増加により、呼吸器疾患の発生率が増加しています。このことは、不健康な食習慣や座りがちなライフスタイルのために体重に関連した健康上の懸念が増加していることと相まって、市場にプラスの影響を与えています。これとは別に、さまざまな遺伝性疾患や生活習慣病の急増、がんの早期診断と治療の利点に関する個人やヘルスケア専門家の意識の高まりが、市場の成長を後押ししています。さらに、製薬企業による臨床試験の拡大、個別化医薬品や新世代の医薬品・製剤に対する嗜好の高まりが、市場の成長を後押ししています。これに加えて、製品ポートフォリオを拡大し競争優位を獲得するために、戦略的提携や新製品開発に大手企業が注力する傾向が強まっていることも、市場に明るい展望をもたらしています。さらに、医療インフラと診断技術の大幅な向上が市場の成長を強化すると予測されています。

本レポートで扱う主な質問

  • 免疫チェックポイント阻害薬の市場の世界市場規模は？
  • 2025-2033年における世界の免疫チェックポイント阻害薬の市場の予想成長率は？
  • 世界の免疫チェックポイント阻害薬の市場を牽引する主要因は何か？
  • 世界の免疫チェックポイント阻害薬の市場に対するCOVID-19の影響は？
  • 世界の免疫チェックポイント阻害薬の市場のタイプ別内訳は？
  • 免疫チェックポイント阻害薬の市場の世界市場における流通チャネル別の内訳は？
  • 世界の免疫チェックポイント阻害薬の市場の用途別内訳は？
  • 世界の免疫チェックポイント阻害薬の市場における主要地域は？
  • 世界の免疫チェックポイント阻害薬の市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の免疫チェックポイント阻害薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • CTLA-4阻害薬
    • 市場動向
    • 市場予測
  • PD-1阻害薬
    • 市場動向
    • 市場予測
  • PD-L1阻害薬
    • 市場動向
    • 市場予測

第7章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 肺がん
    • 市場動向
    • 市場予測
  • 膀胱がん
    • 市場動向
    • 市場予測
  • 悪性黒色腫
    • 市場動向
    • 市場予測
  • 大腸がん
    • 市場動向
    • 市場予測
  • ホジキンリンパ腫
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • GSK plc
    • Merck & Co. Inc.
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Seagen Inc.
図表

List of Figures

  • Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
  • Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
  • Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
  • Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players
目次
Product Code: SR112025A7221

The global immune checkpoint inhibitors market size reached USD 49.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 168.6 Billion by 2033, exhibiting a growth rate (CAGR) of 14.6% during 2025-2033. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

Type Insights:

  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Application Insights:

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Colorectal Cancer
  • Hodgkin Lymphoma
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.

Key Questions Answered in This Report

  • 1. How big is the global immune checkpoint inhibitors market?
  • 2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2025-2033?
  • 3. What are the key factors driving the global immune checkpoint inhibitors market?
  • 4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
  • 5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
  • 6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
  • 7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
  • 8. What are the key regions in the global immune checkpoint inhibitors market?
  • 9. Who are the key players/companies in the global immune checkpoint inhibitors market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immune Checkpoint Inhibitors Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 CTLA-4 Inhibitor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 PD-1 Inhibitor
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 PD-L1 Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bladder Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Colorectal Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hodgkin Lymphoma
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ono Pharmaceutical Co. Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Regeneron Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Seagen Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.